Rosetta Genomics and Biocept Advance Collaboration to Proof-of-Concept Studies Aimed at microRNA Profiling of Circulating Tumor Cells to Enhance Lung Cancer Diagnosis
Companies to take next step following successful completion of feasibility studies
In the next phase of the collaboration, Rosetta and
Feasibility studies were conducted using two lung cancer cell lines: A549 and H727. The objectives were to determine whether Biocept's preservatives affect the microRNA profile of tested cell lines and to determine the feasibility of profiling microRNAs using Rosetta's platform in samples containing a small number of cells.
-
In the first study,
Biocept treated two cell lines with two types of preservatives. The cells were then sent to Rosetta for processing on its microarray platform to assess the effects of these preservatives on miRNA expression. The results indicated that the expression of Rosetta's lung cancer microRNA biomarker panel was unaffected. - In the second study, Rosetta used its qRT-PCR platform to profile samples containing a small number of cancer cells (10-200 cells), using a select list of microRNAs based on the first study. The results showed that all tested microRNAs were detected in all samples tested.
"We are excited about advancing this collaboration to proof-of-concept
studies and to determine opportunities for next steps in developing
advanced diagnostics," noted
"Our liquid biopsy approach has advantages over invasive and expensive
surgical tissue biopsy procedures and we are encouraged about the
potential to expand its use by combining our CTC and Rosetta's microRNA
technologies," said
About RosettaGX Cancer Testing Services
RosettaGX Cancer Tests are a series of microRNA-based and other
molecular diagnostic testing services offered by
About
Rosetta develops and commercializes a full range of microRNA-based and
other molecular diagnostics. Rosetta's integrative research platform
combining bioinformatics and state-of-the-art laboratory processes has
led to the discovery of hundreds of biologically validated novel human
microRNAs. Building on its strong patent position and proprietary
platform technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full range of
microRNA-based diagnostic tools. Through the acquisition of
PersonalizeDx, Rosetta offers core FISH, IHC and PCR-based testing
capabilities and partnerships in oncology and urology that provide
additional content and platforms that complement the Rosetta offerings.
Rosetta's and PersonalizeDx's cancer testing services are commercially
available through the
About
Rosetta Genomics Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future
expectations, plans and prospects, including but not limited
to statements that the collaboration between Rosetta and
Biocept Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although
View source version on businesswire.com: http://www.businesswire.com/news/home/20151214005402/en/
investors@rosettagenomics.com
or
LHA
afields@lhai.com
or
LHA
jcain@lhai.com
Source:
News Provided by Acquire Media